Akebia Therapeutics, Inc.
DE ˙ DB ˙ US00972D1054
0,83 € ↓ -0,02 (-2,69%)
2026-06-03
AKTIENPREIS
SecurityDE:AX9 / Akebia Therapeutics, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership2,854,586 shares
Latest Disclosed Value $ 3,967,875
Citigroup Inc ownership in AX9 / Akebia Therapeutics, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 2,854,586 shares of Akebia Therapeutics, Inc. (DE:AX9) valued at $3,257,083 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 2,436,203 shares of Akebia Therapeutics, Inc.. This represents a change in shares of 17.17% during the quarter. The current value of the position is $2,371,590 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (AX9) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:AX9 / Akebia Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F AKEBIA THREAPEUTICS COM 00972D105 2,854,586 418,383 17.17 3,968 1.15 0.0017
2026-02-13 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 2,436,203 519,511 27.10 3,922 -25.04 0.0017
2025-11-10 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,916,692 1,782,162 1,324.73 5,233 969.94 0.0023
2025-08-11 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 134,530 -171,470 -56.04 490 -16.70 0.0002
2025-05-12 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 306,000 69,214 29.23 588 30.73 0.0003
2025-02-12 2024-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 236,786 85,381 56.39 450 125.63 0.0003
2024-11-12 2024-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 151,405 104,845 225.18 200 323.40 0.0001
2024-08-12 2024-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 46,560 -141,265 -75.21 47 -86.30 0.0000
2024-05-10 2024-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 187,825 -117,781 -38.54 344 -9.26 0.0002
2024-02-09 2023-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 305,606 152,869 100.09 379 117.24 0.0003
2023-12-06 2023-09-30 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 152,737 152,688 311,608.16 174 0.0001
2023-11-09 2023-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 152,737 152,688 174 0.0001
2023-08-10 2023-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 49 0 0.00 0 0.0000
2023-05-11 2023-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 49 -677 -93.25 0 0.0000
2023-02-09 2022-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 726 -45,897 -98.44 0 -100.00 0.0000
2022-11-10 2022-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 46,623 -63,664 -57.73 15 -61.54 0.0000
2022-08-10 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 110,287 -126,503 -53.42 39 -77.06 0.0000
2022-05-12 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 236,790 -439,396 -64.98 170 -88.87 0.0001
2022-02-10 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 676,186 227,543 50.72 1,528 18.27 0.0008
2021-11-10 2021-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 448,643 -464,125 -50.85 1,292 -62.65 0.0008
2021-08-10 2021-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 912,768 -221,780 -19.55 3,459 -9.92 0.0021
2021-05-13 2021-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 1,134,548 1,090,721 2,488.70 3,840 3,021.95 0.0025
2021-02-11 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 43,827 28,335 182.90 123 215.38 0.0001
2020-11-12 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 15,492 -592,605 -97.45 39 -99.53 0.0000
2020-08-12 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 608,097 509,968 519.69 8,258 1,009.95 0.0064
2020-05-12 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 98,129 30,762 45.66 744 75.06 0.0007
2020-02-12 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 67,367 -256,337 -79.19 425 -66.51 0.0003
2019-11-08 2019-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 323,704 -17,508 -5.13 1,269 -23.18 0.0010
2019-08-12 2019-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 341,212 302,319 777.31 1,652 419.50 0.0013
2019-05-13 2019-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 38,893 -258,612 -86.93 318 -80.67 0.0003
2019-02-12 2018-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 297,505 245,988 477.49 1,645 261.54 0.0017
2018-11-13 2018-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 51,517 7,052 15.86 455 2.48 0.0004
2018-08-10 2018-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 44,465 8,606 24.00 444 29.82 0.0004
2018-05-11 2018-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 35,859 -6,413 -15.17 342 -45.63 0.0003
2018-02-12 2017-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 42,272 14,971 54.84 629 17.13 0.0005
2017-11-13 2017-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 27,301 23,321 585.95 537 842.11 0.0004
2017-08-11 2017-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 3,980 3,658 1,136.02 57 1,800.00 0.0001
2017-05-12 2017-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 322 -8,744 -96.45 3 -96.81 0.0000
2017-02-10 2016-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 9,066 9,041 36,164.00 94 0.0001
2016-11-10 2016-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 25 -8,094 -99.69 0 -100.00
2016-08-12 2016-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 8,119 -14,991 -64.87 61 -70.67 0.0001
2016-05-13 2016-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 23,110 13,758 147.11 208 71.90 0.0002
2016-02-12 2015-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 9,352 8,642 1,217.18 121 1,628.57 0.0001
2015-11-13 2015-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 710 -3,330 -82.43 7 -83.33 0.0000
2015-08-13 2015-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 4,040 940 30.32 42 23.53 0.0000
2015-05-14 2015-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 3,100 -2,516 -44.80 34 -47.69 0.0000
2015-02-17 2014-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 5,616 5,334 1,891.49 65 983.33 0.0001
2014-11-14 2014-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 282 176 166.04 6 100.00 0.0000
2014-08-14 2014-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 106 106 3 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-08-10 2022-06-30 13F AKEBIA THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-05-12 2022-03-31 13F AKEBIA THERAPEUTICS COM Call 275,000 10.00 197 -65.13 n/a n/a n/a
2022-02-10 2021-12-31 13F AKEBIA THERAPEUTICS COM Call 250,000 565 n/a n/a n/a
2020-05-12 2020-03-31 13F AKEBIA THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-12 2019-12-31 13F AKEBIA THERAPEUTICS COM Call 2,997 0.00 19 58.33 n/a n/a n/a
2019-11-08 2019-09-30 13F AKEBIA THERAPEUTICS COM Call 2,997 0.00 12 -20.00 n/a n/a n/a
2019-08-12 2019-06-30 13F AKEBIA THERAPEUTICS COM Call 2,997 0.00 15 -40.00 n/a n/a n/a
2019-05-13 2019-03-31 13F AKEBIA THERAPEUTICS COM Call 2,997 -59.50 25 -39.02 n/a n/a n/a
2019-02-12 2018-12-31 13F AKEBIA THERAPEUTICS COM Call 7,400 41 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-05-12 2020-03-31 13F AKEBIA THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-12 2019-12-31 13F AKEBIA THERAPEUTICS COM Put 3,478 0.00 22 57.14 n/a n/a n/a
2019-11-08 2019-09-30 13F AKEBIA THERAPEUTICS COM Put 3,478 -24.80 14 -36.36 n/a n/a n/a
2019-08-12 2019-06-30 13F AKEBIA THERAPEUTICS COM Put 4,625 -66.92 22 -80.87 n/a n/a n/a
2019-05-13 2019-03-31 13F AKEBIA THERAPEUTICS COM Put 13,982 25.55 115 85.48 n/a n/a n/a
2019-02-12 2018-12-31 13F AKEBIA THERAPEUTICS COM Put 11,137 62 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.